AusBiotech supports research exemption in patent reform Bill
22 June, 2011 by Tim DeanAusBiotech has welcomed the research exemption from patent infringement in Australia’s intellectual property reform bill introduced into Parliament today.
BIO 2011 biotech profile: Mesoblast’s vision from the top
21 June, 2011 by Tim DeanMesoblast CEO, Professor Silviu Itescu , was instrumental in cutting the historic billion-dollar deal with Cephalon. He speaks to ALS about how he did it.
BIO 2011 biotech profile: Mesoblast
20 June, 2011 by Tim DeanMesoblast has been making great strides in its stem cell technology over the past several years, and it all paid off with a game changing deal cut with US pharma Cephalon late last year.
R&D Tax Credit will boost small biotechs
17 June, 2011 by Tim DeanThe R&D Tax Credit will give a much needed boost to small cap biotechs, says Karen Sinclair, past president of LESANZ.
R&D Tax Credit (finally) gets the go ahead
15 June, 2011 by Tim DeanCrossbench support has paved the way for the beleaguered R&D Tax Credit to pass the Senate in the next session, coming into effect as of 1 July 2011.
QRxPharma to file NDA within two months
15 June, 2011 by Staff WritersAfter completing a phase III safety trial of analgesic MoxDuo IR QRxPharma (ASX: QRX) is winding up for its New Drug Application within two months time.
BIO 2011 special report: The third wave of Australian biotechs
15 June, 2011 by Tim DeanFollowing the successes of the last six months in Australian biotechnology, the question becomes: who’s next?
BIO 2011 special report: Australian biotechnology comes of age
14 June, 2011 by Tim DeanThe Australian biotechnology industry has entered a new phase, with several high profile deals demonstrating the sector can truly deliver. Now attention is turning to what comes next.
Bluechiip to list on ASX tomorrow
08 June, 2011 by Tim DeanWireless tracking and sensor company Bluechiip will list on the ASX on Thursday 9 June 2011 after several months winding up to the big day.
Otifex lands $1.1m to develop treatment for childhood hearing problems
07 June, 2011 by Staff WritersMelbourne-based biotech plans to develop a nasal spray to treat otitis media with effusion (OME).
Stem cell breakthrough offers hope for treating kidney disease
18 May, 2011 by Tim DeanAustralian scientists have generated induced pluripotent stem cells from adult differentiated kidney cells, opening up the possibility of better understanding and treatment of kidney disease.
Mesoblast deal inspires Teva to swoop on Cephalon
05 May, 2011 by Tim DeanTeva has outbid Valeant in its offer to buy Cephalon, citing interest in Mesoblast's stem cell therapies.
iCeutica acquired by US pharma
28 April, 2011 by Tim DeanPerth-based iCeutica has been bought up by US pharma company Iroko for a sum reportedly ten times its 2005 valuation.
Feature: Strengthening plant defensins
19 April, 2011 by Graeme O'NeillLa Trobe University’s Marilyn Anderson is developing techniques to boost the natural defences of plants to disease.
Feature: Biodefender
15 April, 2011 by Graeme O'NeillCSIRO Plant Industry vine disease expert, Dr Ian Dry, is strengthening our defences against fungal and insect attacks against crops.
